INTRODUCTION
Atrial fibrillation (AF) is the most common heart rhythm disorder and the global burden of AF and its high risk of stroke are well documented in both Western and Asia countries [1] [2] [3] [4] . Findings from the prospective community-based Rotterdam study demonstrate that the number of AF patients aged >55 years old will be more than double to 17.9 million in European Union from 2010 to 2060 [5] . An investigation in the southwest of China has shown that the prevalence of AF had increased 20-fold over an 11-year period, while AF-related stroke increased 13-fold [4] . Due to the increasing epidemic of AF with an aging population, AF burden has become a growing public health concern worldwide. In recent years, sex related differences in incidence, presentations, outcomes and clinical management among patients with nonvalvular AF have been demonstrated in previous epidemiologic studies from Western countries [6, 7] , with a greater prevalence of AF usually among males, while female patients are at higher risk of stroke and thromboembolism [8] .
Indeed, females with AF tended to be older and sicker, with a worse cardiovascular risk profile and a lower quality of life [9] . In the original Framingham cohort, for example, AF was associated with a 1.9 fold higher risk of death among female patients compared to males [10] . The Anticoagulation and Risk factors In Atrial fibrillation (ATRIA) cohort prospectively studied 13 559 AF patients and have shown that females were at 1.6 fold higher risk for AF-related thromboembolism than males [11] . The increased risk of stroke among females with AF can be further demonstrated by a systemic review and meta-analysis [8] . Due to the higher risk of stroke among females AF patients, female
sex has been incorporated in CHA2DS2-VASc score as a risk factor of stroke or systemic embolism among AF patients [12] .
However, most sex-related investigations of AF are based on data from Western populations [8] , whilst few studies have investigated the impact of sex on clinical characteristics and inpatient outcomes amongst nonvalvular AF patients from China.
Hence, the aim of this study was to investigate sex-related differences in clinical characteristics and inpatient outcomes amongst a hospitalised cohort of Chinese nonvalvular AF patients, in the Nanchang Atrial Fibrillation Project.
METHODS

Study population
All consecutive patients with nonvalvular AF admitted to our tertiary care hospital, the second affiliated hospital of Nanchang university, from May 2011 till December 2013, were included. This is a teaching hospital which covers the health management of a population of over 5 million. Patients admitted with a concomitant diagnosis of AF were eligible for inclusion in this registry. Those with AF combined with the presence of valvular heart disease requiring management were excluded. The diagnosis of AF was made by the attending physician confirmed with an electrocardiogram or Holter monitor.
Data collection
The demographic and clinical characteristics of included patients were extracted from our hospital electronic data system, including date of birth, sex, length of stay, diagnoses 
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Statistical analysis
All analyses were performed using the IBM SPSS Version 21.0 (SPSS, Inc., Chicago, IL).
The distribution of continuous variables was examined by the Kolmogorov-Smirnov test.
Normally distributed variables are presented as mean (standard deviation, SD) and 
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RESULTS
In total, 3327 AF patients were admitted between May 2011 and December 2013. Of these, 875 (26.3%) were excluded due to the presence of valvular heart disease requiring management, and 10 were excluded for insufficient basic clinical data, leaving a final cohort population of 2442 non-valvular AF patients ( Figure 1 ). Of the whole cohort, there were 1453 patients hospitalised in the cardiovascular department, and 1030 patients admitted with a primary or secondary diagnosis of AF.
Males were more prevalent than females (56.3% vs 43.7%, P<0.0001 
Concomitant diseases
There were no significant sex differences in the subtypes of AF (p=0.13). Hypertension and heart failure were the most common concomitant diseases among the whole cohort.
As shown in Table 1 , females had a significantly higher prevalence of hypertension, diabetes, and hyperthyroidism, but a lower prevalence of coronary artery disease, cardiomyopathy, chronic renal disease, and cancer than males.
CHA2DS2-VASc and CHADS2 scores
Both the median CHA2DS2-VASc and CHADS2 scores were higher in female AF patients (p<0.0001) (see Table 2 ). When those patients with CHADS2 of 0 or 1 were further refined using CHA2DS2-VASc score, more female patients were classified into the group of CHA2DS2-VASc ≥2 (p=0.009).
Medication therapy at discharge
Among the 2389 (97.8%) patients discharged alive, there were low proportions of patients with intervention therapy such as catheter ablation or pacemakers, 3.0% and 2.2%, respectively (Table 3) . No sex differences were evident. More female patients received angiotensin receptor blockers (ARB) and calcium channel blockers (CCB), but there were no statistical differences in other drugs.
Antithrombotic therapy
Only 173 (7.3%) patients received warfarin prior to admission; this increased to 791 (33.3%) during hospitalization (see Table 3 ). No information on quality of anticoagulation control, as reflected by time in therapeutic range (TTR) was recorded.
Rates of aspirin or clopidogrel use at discharge were 38.9% and 10.7%, respectively. No sex differences were evident in the choice of antithrombotic therapy.
Inpatient outcomes
Fifty-three (2.2%) patients died during hospitalization, with no sex differences (see Table 4 ). The incidence rates of inpatient ischaemic stroke or major bleeding were 11.6% and 3.3%, respectively. Median (IQR) length of stay was 10 (7-14) days. There were no sex differences in these inpatient outcomes.
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DISCUSSION
Since there is some evidence that AF patients from Asian cohorts are at particularly high risk of adverse outcomes, further information is needed on their clinical epidemiology.
In the present study, sex-related differences in clinical characteristics and stroke risk profile were evident in Chinese nonvalvular AF patients. Compared with males, females patients were significantly older with higher CHADS2 and CHA2DS2-VASc scores.
Hypertension, diabetes, and hyperthyroidism were more commonly found with AF in females, but males had a higher prevalence of concomitant diseases including coronary artery disease, cardiomyopathy, chronic renal disease, and cancer. Previous ischemic stroke/TIA/TE was an important predictor of inpatient mortality in both males and
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Consistent with previous studies on other populations [9, 14] , our analyses shows that more of the patients admitted with AF were male, but that female AF patients were significantly older with a higher proportion in the elderly group (≥75 years), which can perhaps be explained by the longer life expectancy for females. The higher incidence of AF in males and the older age in females is also consistent with a study from Southwest of China [4] but contrasts with a recent cross-sectional study in rural China which reported no significant sex differences at any age [15] . The discrepancy in these findings may be due the study setting and patient demography from different districts.
Female AF patients tended to be more symptomatic and may be more likely to seek medical attention as a result [9] . However, there was no impact of sex on antithrombotic therapy. The use of warfarin prior to admission was sub-optimal, with only 7.3% receiving warfarin. This figure increased to 33.3% during hospitalization, with no sex differences evident.
These data can be further reinforced by the data from a prospective multicentre international observational registry, which demonstrates the comparable anticoagulant use in males and females overall (60.9% versus 60.8%) [16] . However, among those patients with CHA2DS2-VASc score of ≥2, 64.6% of males versus 61.6% of females received anticoagulant therapy in this global registry, with combination therapy with anticoagulant plus antiplatelet more frequently used in males. Another study based on data from 11 general practices in Darlington in the UK found more females who were
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The low overall use of warfarin is compounded by lack of recorded information on TTR, which has been closely related to the efficacy and safety related to warfarin; current guidelines recommend a TTR of >70% [18, 19] . None of our patients were using the non-Vitamin K oral anticoagulants (NOACs), and whether their subsequent widespread introduction would improve anticoagulation uptake remains uncertain.
Sex differences in the risk of thromboembolism and death have been shown among AF patients in several large Scandinavian nationwide cohort studies [20] [21] [22] [23] . Female sex has been established as a risk factor for thromboembolism and death among AF patients, and incorporated in the CHA2DS2-VASc score. Nonetheless, whether female sex per se is intrinsically associated with higher thromboembolic events has been debated. In a Danish study, a lower stroke risk was identified for females in relatively young patients with AF [22] . According to the current results, both CHA2DS2-VASc and CHADS2 scores were higher in female patients, indicating greater risk of stroke for females than males.
Regardless of female sex as a risk factor, the higher CHA2DS2-VASc scores were observed among female patients, as reflected by more females with score of ≥3 than males with score of ≥2. Additionally, more female patients with CHADS2 of 0 or 1 were identified to have higher risk of stroke, presented with CHA2DS2-VASc of ≥ 2. Hence, our data may further support the greater risk of thromboembolic events among female AF patients.
For inpatient outcomes, no significant sex differences were found. The incidence of inpatient death and inpatient ischemic stroke was comparable between males and females. Previous ischemic stroke/TIA/TE was independently associated with
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Our data also show that female AF patients with hypertension had a lower risk of inpatient death, a finding that was not consistent with the traditional conception. One possible explanation is the underdiagnosis of hypertension among female patients and those with hypertension were well-treated with antihypertensive drugs which can protect patients from death. However, a slightly higher mean systolic BP was seen amongst females and the mortality observation could also be a chance finding or residual confounding.
Limitations
There are several limitations to be addressed in the present study. Firstly, the data was extracted based on medical records from a single centre, which may not be generalizable to the whole population of China. Secondly, AF was not the primary or secondary cause for admission in 1412 (57.8%) patients. Third, only risk factors associated with inpatient mortality were analyzed for both males and females. Finally, all included patients were admitted to various departments, not limited to cardiovascular department.
In conclusion, sex related differences were evident in clinical characteristics and stroke risk profile among Chinese patients with nonvalvular AF. Previous ischemic stroke/TIA/TE was an important predictor of inpatient mortality in both males and females. However, no sex disparity was evident in the low antithrombotic therapy use or inpatient mortality. Figure 1 . Flow chart of the study cohort recruitment
